Andrew J. Armstrong, Md

This study tests a mix of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in men with a rare, aggressive form of prostate cancer. The goal is to see if the combination can stop the cancer from growing for at least 6 months. Participants receive up to 10 cycles of…